

## Research Article



# Endoscopic Thoracic Sympathectomy for the Treatment of Hyperhidrosis

Seyed Hesamaddin Banihashemi<sup>1\*</sup>, Seyedeh Hanan Banihashemi<sup>2</sup>, Ali Foroutan<sup>3</sup><sup>1</sup>Department of Thoracic Surgery, Faculty of Medicine, Hormozgan University of Medical Sciences, Bandar Abbas, Iran<sup>2</sup>Student Research Committee, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran<sup>3</sup>Department of Plastic Surgery, School of Medicine, Iran University of Medical Sciences, Tehran Iran

## Abstract

**Background:** Although hyperhidrosis is regarded as a benign sympathetic disorder, it can have a significant psychosocial impact on affected individuals while markedly affecting their quality of life (QoL).**Objectives:** We aimed to evaluate the effects of endoscopic thoracic sympathectomy (ETS) on the treatment of primary hyperhidrosis and patients' QoL.**Methods:** This prospective interventional study included patients with primary hyperhidrosis referred to Shahid Mohammadi Hospital, Bandar Abbas, Iran, for ETS during 2012-2019. General characteristics including age, sex, and body mass index (BMI) were recorded for all patients. All participants underwent ETS by a single experienced surgeon. Patients were evaluated twice; once before the procedure and once one month after the procedure. The sites of hyperhidrosis, Hyperhidrosis Disease Severity Scale (HDSS), and QoL were the evaluated variables. Patients' satisfaction, compensatory hyperhidrosis, and procedural complications such as pneumothorax were also assessed on follow-up.**Results:** From the 47 patients evaluated in this study with a mean  $\pm$  SD age of  $28.2 \pm 1.21$  years, 27 (57.4%) were men. No patient experienced compensatory hyperhidrosis and procedural complications after the procedure. Also, 45 (95.7%) patients were 100% satisfied and 2 (4.3%) were 90% satisfied with the procedure. There was a significant reduction in the number of hyperhidrosis sites and HDSS score after one month compared with baseline ( $P=0.006$  and  $P<0.001$ , respectively). Moreover, the QoL significantly improved after the procedure ( $P<0.001$ ).**Conclusion:** ETS appears to be very safe and effective for the treatment of primary hyperhidrosis in terms of the reduction of hyperhidrosis sites and HDSS score, as well as improving QoL and patient satisfaction.**Keywords:** Hyperhidrosis, Quality of life, Endoscopic thoracic sympathectomy, Disease severity

## \*Correspondence to

Seyed Hesamaddin  
Banihashemi,  
Email:  
hesamaddinbanihashemi@  
gmail.com

Received June 15, 2021, Accepted: August 28, 2021, Published Online: September 29, 2021

## Background

Characterized by excessive, symmetric, focal perspiration of the craniofacial region, palms, soles, and axillae, primary hyperhidrosis is considered a benign sympathetic disorder triggered by heat, stressful situations, or physical activity (1,2). Hyperhidrosis can cause psychosocial problems and therefore significantly impact quality of life (QoL) (3,4).

The underlying cause of primary or idiopathic hyperhidrosis is not well understood; however, it is believed to occur as a result of the aberrant or increased sympathetic stimulation of the eccrine sweat glands which are distributed all over the body but mostly concentrated in the axillae, face, palms, and soles (5). Accordingly, the basal level of sweat production is higher than normal in individuals with primary hyperhidrosis. They also have an increased response to normal stimuli, such as physical or emotional stress (5).

Different strategies exist for the treatment of hyperhidrosis, including topical therapies and botulinum

toxin injection as first- and second-line treatments, as well as oral anticholinergics, iontophoresis, microwave energy, fractionated microneedle radiofrequency, local surgical therapy, and endoscopic thoracic sympathectomy (ETS) (5-11).

Palmar primary hyperhidrosis is the main indication for ETS, as in these patients, symptoms almost completely disappear and QoL is completely improved. However, this procedure can also yield good results for axillary and facial hyperhidrosis (12). The most common and important side effect of ETS is compensatory hyperhidrosis, with a higher risk in patients with facial hyperhidrosis undergoing ETS, because of the interruption of the sympathetic trunk at a higher level (12). Therefore, patient selection for ETS is of utmost importance.

## Objectives

We aimed to evaluate the effects of ETS on the treatment of primary hyperhidrosis as well as the patients' QoL.

## Patients and Methods

### Participants

This prospective interventional study included patients with primary hyperhidrosis referred to Shahid Mohammadi Hospital, Bandar Abbas, Iran for ETS from March 21, 2012 to March 20, 2019. Inclusion criteria were dissatisfaction with clinical or medical treatment or failure of clinical treatment, as well as severe hyperhidrosis (a score of 3 or 4 on the Hyperhidrosis Disease Severity Scale [HDSS]). Patients with secondary causes of hyperhidrosis, including endocrine diseases (diabetes mellitus, hyperthyroidism, and hyperpituitarism), neurological diseases (peripheral nerve injury, Parkinson's disease, reflex sympathetic dystrophy, spinal cord injury, and Arnold-Chiari malformation), malignancies (pheochromocytoma and chronic pulmonary diseases), and psychiatric diseases such as generalized anxiety disorder were excluded from the study. Also, patients with a history of pneumothorax, tuberculosis, pneumonia, pleural effusion, and previous intrathoracic surgical interventions or any other condition that might have caused pleuropulmonary adhesions were excluded.

### Study design

General characteristics including age, sex, and body mass index (BMI) were recorded for all patients and written informed consent was obtained. All participants were operated by the same experienced surgeon.

All patients underwent general anesthesia and were intubated with a single-lumen endotracheal tube. During the procedure, the patients were in semi-sitting position (45°) with their arms abducted at 90° using two subscapular cushions allowing the lateral motion of the surgery table and the free movement of the surgeon. The procedure was first performed on one side and then continued to the other side. A small 5cm-pack was placed under the shoulders to elevate the opening site of the ports. Two ports were used; one for the camera and the other for the cautery. The camera port was placed within the 3<sup>rd</sup> intercostal space in the anterior axillary line, lateral to the pectoralis muscles. The camera was inserted following a 7-8 mm Hg CO<sub>2</sub> flow. The cautery was inserted at the 4<sup>th</sup> intercostal space in the midaxillary line. The second rib was visualized at the apex of the thorax. All procedures were done below the upper border of the 2<sup>nd</sup> rib. The sympathetic ganglion is usually visualized on the neck of the ribs. If there was difficulty visualizing the sympathetic ganglion, the head of the cautery was used to specify its position. The pleura over the sympathetic chain was opened using the cautery. Depending on the site of hyperhidrosis, the necks of the ribs were cauterized from the lower border of the 2<sup>nd</sup> rib to the 4<sup>th</sup> rib. Three to four cm lateral to the rib necks, the branches of the nerve of Kuntz, were also cauterized. CO<sub>2</sub> gas was removed as much as possible to avoid CO<sub>2</sub> pneumothorax.

Patients were evaluated twice; once before the procedure

and once one month after the procedure. Evaluations included the sites of hyperhidrosis, HDSS score, and QoL. Patients' satisfaction, compensatory hyperhidrosis, and procedural complications such as pneumothorax were also assessed upon follow-up.

The HDSS has four statements scored 1-4 and individuals can only mark one of these statements. A score of 1 or 2 shows mild to moderate hyperhidrosis, while a score of 3 or 4 indicates severe hyperhidrosis (13). We evaluated the Persian version of HDSS in a pilot study and found an internal consistency of 0.85 as well as Cronbach's alpha of 0.93. QoL was evaluated using a 20-item questionnaire first developed by Amir and colleagues (14). It consists of four domains, including personal, emotional, functional-social, and special conditions, with scores ranging from 20 to 100 and higher scores indicating worse QoL. We also evaluated the reliability and validity of the Persian version of this QoL questionnaire and found an internal consistency of 0.81 as well as Cronbach's alpha of 0.91. Patients' satisfaction with ETS was assessed using a four-choice item based on their personal judgement. The answers were 100%, 90%, 75%, and <50% satisfied with the procedure.

### Data analysis

We used the Statistical Package for the Social Sciences (SPSS) software (version 26.0, Armonk, NY: IBM Corp.) for data analysis. Means and standard deviations were used to describe quantitative variables, and frequencies and percentages for qualitative variables. Chi-square test was used to compare qualitative variables before the procedure and at follow-up. Based on the results of Kolmogorov-Smirnov normality test, paired *t* test was used to compare quantitative variables before and after the procedure.  $P \leq 0.05$  were considered statistically significant.

### Results

From the 47 patients included in this study (mean  $\pm$  SD age =  $28.2 \pm 1.21$  years), 27 (57.4%) were men and 20 (42.6%) were women (Table 1). The patients' QoL improved significantly and HDSS score significantly decreased on follow-up compared with baseline ( $P < 0.001$ ). Also, there was a significant reduction in the number of hyperhidrosis sites on follow-up ( $P = 0.006$ ) (Table 2).

Compensatory hyperhidrosis occurred in none of the patients and there were no procedural complications. As for patients' satisfaction with the procedure, 45 (95.7%) were 100% satisfied and 2 (4.3%) were 90% satisfied.

### Discussion

In the current study we found that ETS significantly improved the QoL of patients with primary hyperhidrosis. Also, all patients were 90%-100% satisfied with the

**Table 1.** General Characteristics of the Study Population

Variables	Total (n=47)
Gender, No. (%)	
Male	27 (57.4)
Female	20 (42.6)
Age (y), mean $\pm$ SD	28.2 $\pm$ 1.21
BMI (kg/m <sup>2</sup> ), mean $\pm$ SD	23.82 $\pm$ 1.05

Abbreviations: N, number; SD, standard deviation; BMI, body mass index

**Table 2.** Comparison of Sites of Hyperhidrosis, HDSS, and QoL Before and After the Procedure

Variables	Before	After	P Value*
Number of hyperhidrosis sites, mean $\pm$ SD	2.01 $\pm$ 0.21	0.12 $\pm$ 0.04	0.006
HDSS, mean $\pm$ SD	3.78 $\pm$ 0.45	1.54 $\pm$ 0.22	<0.001
QoL, mean $\pm$ SD	82.48 $\pm$ 8.26	32.44 $\pm$ 5.87	<0.001

Abbreviations: SD, standard deviation; HDSS, Hyperhidrosis Disease Severity Scale; QoL, quality of life.

\*Analyzed by paired *t* test.

procedure. Additionally, ETS significantly reduced the number of hyperhidrosis sites and HDSS in these patients after one month compared with the baseline. Furthermore, no cases of compensatory hyperhidrosis were reported by any of the patients after the procedure.

Vannucci and Araujo performed sympathectomies on 739 patients. Similar to our findings 95.9% of the patients were very satisfied with the procedure 30 days after surgery; nevertheless, they reported a slight insignificant decrease in the patients' satisfaction over two years after surgery (12). This shows that patients undergoing ETS should be followed up for a longer period to better evaluate satisfaction with the procedure.

We had no cases of compensatory hyperhidrosis in our patients. In a meta-analysis of eight randomized trials including 1200 patients undergoing video-assisted thoracoscopic sympathectomy for palmar hyperhidrosis, the risk of compensatory hyperhidrosis was lower with sympathectomy at lower segments compared to higher segments (15). Zhang and colleagues demonstrated comparable results in their meta-analysis of 10 articles consisting of 1195 patients (16). The inclusion of patients with different sites of hyperhidrosis, as well as the relatively small number of patients evaluated in our study can be responsible for the difference between the results of these two studies and ours.

Wolosker and colleagues reported compensatory hyperhidrosis in less than 10% of their patients after ETS (17). ETS is primarily performed on non-obese patients as obesity puts patients at a higher risk of compensatory hyperhidrosis (18). Nonetheless, the mean BMI of the patients in the mentioned study was 21.6 kg/m<sup>2</sup> while the mean BMI of our patients was 23.82 kg/m<sup>2</sup>. Factors other than BMI, such as the level at which sympathectomy was performed and the severity of hyperhidrosis before the procedure in the two studies could be the potential

explanations for this discrepancy.

In line with our findings regarding the significant improvement in the QoL, Wolosker and colleagues found improved QoL in their study irrespective of the number of hyperhidrosis sites (17). QoL improvement after surgery reflects surgical success (19). Patients' satisfaction is another index to evaluate surgical success. Consistent with our results, Wolosker et al reported that more than 90% of the patients were very satisfied with the procedure; however, 2.6% of their patients had <50% satisfaction. All our patients had 90%-100% satisfaction with ETS. One reason for this can be the occurrence of compensatory hyperhidrosis in some patients in that study compared with none in ours. Compensatory hyperhidrosis can produce personal and social disorders for the patients leading to lower QoL compared to the QoL associated with their main complaint (20-23).

Our study was not without limitations. A limitation of the current study was the small sample size which can affect the generalizability of the results. Also, our study was single-centered. Future studies with a larger sample size are required to confirm our findings.

## Conclusion

In general, ETS can be very effective for the treatment of patients with hyperhidrosis because it can significantly improve their QoL. Furthermore, ETS appears to be a safe procedure with no or minimal procedural complications. However, long-term follow-up of patients can determine the recurrence rate and the occurrence of complications.

## Authors' Contribution

Conceptualization and study validation: SHeB. Study supervision: AF. Implementation: SHeB. Data analysis and interpretation: SHaB. Writing and reviewing: SHeB. All the authors have read and approved the manuscript.

## Availability of Data and Materials

The datasets used and/or analyzed during the current study are available upon request.

## Ethics Approval

The study received ethics approval from the Ethics Committee of Hormozgan University of Medical Sciences and it complies with the statements of the Declaration of Helsinki. Written informed consent was obtained from the parents/guardians of all patients.

## Conflict of Interests

The authors declare that they have no competing interests.

## Funding/Support

No funding was received.

## Acknowledgments

We sincerely appreciate the dedicated efforts of the investigators, the coordinators, the volunteer patients, and the personnel of Bandar Abbas Children's Hospital.

## References

1. McConaghy JR, Fosselman D. Hyperhidrosis: management

- options. *Am Fam Physician*. 2018;97(11):729-34.
2. Dogru MV, Sezen CB, Girgin O, Cansever L, Kocaturk CI, Metin M, et al. Is there any relationship between quality of life and the level of sympathectomy in primary palmar hyperhidrosis? Single-center experience. *Gen Thorac Cardiovasc Surg*. 2020;68(3):273-9. doi: [10.1007/s11748-019-01210-7](#).
  3. Gregoriou S, Sidiropoulou P, Kontochristopoulos G, Rigopoulos D. Management strategies of palmar hyperhidrosis: challenges and solutions. *Clin Cosmet Investig Dermatol*. 2019;12:733-44. doi: [10.2147/ccid.s210973](#).
  4. Wei Y, Xu Z, Li H. The best thoracic sympathectomy level for palmar hyperhidrosis: a meta-analysis. *Indian J Surg*. 2021;83(4):828-34. doi: [10.1007/s12262-020-02512-4](#).
  5. Solish N, Bertucci V, Dansereau A, Hong HC, Lynde C, Lupin M, et al. A comprehensive approach to the recognition, diagnosis, and severity-based treatment of focal hyperhidrosis: recommendations of the Canadian Hyperhidrosis Advisory Committee. *Dermatol Surg*. 2007;33(8):908-23. doi: [10.1111/j.1524-4725.2007.33192.x](#).
  6. Nicholas R, Quddus A, Baker DM. Treatment of primary craniofacial hyperhidrosis: a systematic review. *Am J Clin Dermatol*. 2015;16(5):361-70. doi: [10.1007/s40257-015-0136-6](#).
  7. Saenz JW, Sams RW 2nd, Jamieson B. FPIN's clinical inquiries. Treatment of hyperhidrosis. *Am Fam Physician*. 2011;83(4):465-6.
  8. Jacob C. Treatment of hyperhidrosis with microwave technology. *Semin Cutan Med Surg*. 2013;32(1):2-8.
  9. Abtahi-Naeini B, Fatemi Naeini F, Saffaei A, Behfar S, Pourazizi M, Mirmohammadkhani M, et al. Treatment of primary axillary hyperhidrosis by fractional microneedle radiofrequency: is it still effective after long-term follow-up? *Indian J Dermatol*. 2016;61(2):234. doi: [10.4103/0019-5154.177789](#).
  10. Glaser DA, Galperin TA. Local procedural approaches for axillary hyperhidrosis. *Dermatol Clin*. 2014;32(4):533-40. doi: [10.1016/j.det.2014.06.014](#).
  11. Cerfolio RJ, de Campos JR, Bryant AS, Connery CP, Miller DL, DeCamp MM, et al. The Society of Thoracic Surgeons expert consensus for the surgical treatment of hyperhidrosis. *Ann Thorac Surg*. 2011;91(5):1642-8. doi: [10.1016/j.athoracsur.2011.01.105](#).
  12. Vannucci F, Araújo JA. Thoracic sympathectomy for hyperhidrosis: from surgical indications to clinical results. *J Thorac Dis*. 2017;9(Suppl 3):S178-S92. doi: [10.21037/jtd.2017.04.04](#).
  13. Kowalski JW, Eadie N, Dagget S, Lai PY. Validity and reliability of the hyperhidrosis disease severity scale (HDSS) 1. *J Am Acad Dermatol*. 2004;50(3):51. doi: [10.1016/j.jaad.2003.10.202](#).
  14. Amir M, Arish A, Weinstein Y, Pfeffer M, Levy Y. Impairment in quality of life among patients seeking surgery for hyperhidrosis (excessive sweating): preliminary results. *Isr J Psychiatry Relat Sci*. 2000;37(1):25-31.
  15. Zhang W, Yu D, Jiang H, Xu J, Wei Y. Video-assisted thoracoscopic sympathectomy for palmar hyperhidrosis: a meta-analysis of randomized controlled trials. *PLoS One*. 2016;11(5):e0155184. doi: [10.1371/journal.pone.0155184](#).
  16. Zhang W, Wei Y, Jiang H, Xu J, Yu D. T3 versus T4 thoracoscopic sympathectomy for palmar hyperhidrosis: a meta-analysis and systematic review. *J Surg Res*. 2017;218:124-31. doi: [10.1016/j.jss.2017.05.063](#).
  17. Wolosker N, Leiderman DBD, de Campos JR, Kauffman P, Tedde ML, Yazbek G, et al. Number of preoperative hyperhidrosis sites does not affect the sympathectomy postoperative results and compensatory hyperhidrosis occurrence. *Thorac Cardiovasc Surg*. 2019;67(5):407-14. doi: [10.1055/s-0038-1667317](#).
  18. de Campos JR, Wolosker N, Takeda FR, Kauffman P, Kuzniec S, Jatene FB, et al. The body mass index and level of resection: predictive factors for compensatory sweating after sympathectomy. *Clin Auton Res*. 2005;15(2):116-20. doi: [10.1007/s10286-005-0259-6](#).
  19. Bryant AS, Cerfolio RJ. Satisfaction and compensatory hyperhidrosis rates 5 years and longer after video-assisted thoracoscopic sympathectomy for hyperhidrosis. *J Thorac Cardiovasc Surg*. 2014;147(4):1160-3.e1. doi: [10.1016/j.jtcvs.2013.12.016](#).
  20. Wolosker N, de Campos JR, Kauffman P, de Oliveira LA, Munia MA, Jatene FB. Evaluation of quality of life over time among 453 patients with hyperhidrosis submitted to endoscopic thoracic sympathectomy. *J Vasc Surg*. 2012;55(1):154-6. doi: [10.1016/j.jvs.2011.07.097](#).
  21. Ong W, Lee A, Tan WB, Lomanto D. Long-term results of a randomized controlled trial of T2 versus T2-T3 ablation in endoscopic thoracic sympathectomy for palmar hyperhidrosis. *Surg Endosc*. 2016;30(3):1219-25. doi: [10.1007/s00464-015-4335-2](#).
  22. Wolosker N, de Campos JR, Fukuda JM. Management of compensatory sweating after sympathetic surgery. *Thorac Surg Clin*. 2016;26(4):445-51. doi: [10.1016/j.thorsurg.2016.06.009](#).
  23. Aydemir B, Imamoglu O, Okay T, Celik M. Sympathectomy versus sympathicotomy in palmar hyperhidrosis comparing T3 Ablation. *Thorac Cardiovasc Surg*. 2015;63(8):715-9. doi: [10.1055/s-0034-1384666](#).